ATE432983T1 - Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden - Google Patents
Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werdenInfo
- Publication number
- ATE432983T1 ATE432983T1 AT98945923T AT98945923T ATE432983T1 AT E432983 T1 ATE432983 T1 AT E432983T1 AT 98945923 T AT98945923 T AT 98945923T AT 98945923 T AT98945923 T AT 98945923T AT E432983 T1 ATE432983 T1 AT E432983T1
- Authority
- AT
- Austria
- Prior art keywords
- mage
- hla class
- molecules
- peptides
- peptides presented
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/928,615 US5965535A (en) | 1997-09-12 | 1997-09-12 | Mage-3 peptides presented by HLA class II molecules |
PCT/US1998/018601 WO1999014326A1 (en) | 1997-09-12 | 1998-09-04 | Mage-3 peptides presented by hla class ii molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE432983T1 true ATE432983T1 (de) | 2009-06-15 |
Family
ID=25456537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98945923T ATE432983T1 (de) | 1997-09-12 | 1998-09-04 | Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden |
Country Status (9)
Country | Link |
---|---|
US (2) | US5965535A (de) |
EP (1) | EP1012283B1 (de) |
JP (1) | JP4106179B2 (de) |
AT (1) | ATE432983T1 (de) |
AU (1) | AU757368B2 (de) |
CA (1) | CA2303063C (de) |
DE (1) | DE69840868D1 (de) |
WO (1) | WO1999014326A1 (de) |
ZA (1) | ZA988124B (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE272113T1 (de) * | 1994-02-16 | 2004-08-15 | Crucell Holland Bv | Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
SI1659178T1 (sl) | 1998-02-05 | 2010-07-30 | Glaxosmithkline Biolog Sa | Postopek za čiščenje ali proizvodnjo MAGE proteina |
US6800730B1 (en) * | 1998-10-02 | 2004-10-05 | Ludwig Institute For Cancer Research | Isolated peptides which bind to MHC class II molecules, and uses thereof |
WO2000020445A2 (en) * | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
IT1309584B1 (it) * | 1999-02-26 | 2002-01-24 | San Raffaele Centro Fond | Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso. |
IT1312568B1 (it) * | 1999-05-21 | 2002-04-22 | Genera Spa | Peptidi immunogenici e loro uso. |
US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
US7429639B2 (en) * | 1999-09-29 | 2008-09-30 | Ludwig Institute For Cancer Research | SSX-2 peptides presented by HLA class II molecules |
KR20020047249A (ko) * | 1999-10-19 | 2002-06-21 | 에드워드 에이. 맥더모트, 주니어 | Mage-a12 항원성 펩티드 및 그의 용도 |
US6897288B1 (en) | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
US6605711B1 (en) * | 1999-11-15 | 2003-08-12 | Ludwig Institute For Cancer Research | NY-ESO-1 peptide derivatives, and uses thereof |
EP1235841A4 (de) * | 1999-12-10 | 2006-04-12 | Epimmune Inc | Induzierung von zellulärer immunantwort auf mage2/3 mit hilfe von peptid- und nukleinsäurezubereitungen |
CA2408328C (en) * | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
US7803382B2 (en) | 2001-05-04 | 2010-09-28 | Ludwig Institute For Cancer Research Ltd. | Method for inducing immune response to NY-CO-58 |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
WO2002094994A2 (en) * | 2001-05-18 | 2002-11-28 | Mayo Foundation For Medical Education And Research | Chimeric antigen-specific t cell-activating polypeptides |
AU2003225724A1 (en) | 2002-03-11 | 2003-09-29 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US20040223949A1 (en) * | 2002-10-22 | 2004-11-11 | Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. | Vaccines using high-dose cytokines |
AU2003287557A1 (en) * | 2002-11-07 | 2004-06-03 | Lung-Ji Chang | Modified dendritic cells |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
US20070154889A1 (en) * | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
US7858743B2 (en) * | 2004-09-09 | 2010-12-28 | Ludwig Institute For Cancer Research | SSX-4 peptides presented by HLA class II molecules |
US20090169573A1 (en) * | 2004-10-20 | 2009-07-02 | Erwin Schultz | T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use |
WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
CA2836117C (en) | 2009-12-10 | 2017-08-15 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
US8435795B2 (en) | 2010-01-19 | 2013-05-07 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
RU2684211C2 (ru) * | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
CN109893648A (zh) * | 2013-06-28 | 2019-06-18 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
TWI546381B (zh) * | 2014-05-30 | 2016-08-21 | 中央研究院 | 用以標的黑色素瘤相關抗原a3胜肽之寡核苷酸適體及其用途 |
BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
SG11201807036QA (en) | 2016-02-26 | 2018-09-27 | Auckland Uniservices Ltd | Amino acid and peptide conjugates and conjugation process |
US10441509B2 (en) * | 2018-03-16 | 2019-10-15 | Berkshire Biomedical, LLC | Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9019409D0 (en) * | 1990-09-05 | 1990-10-17 | Pfizer Ltd | Therapeutic agents |
US5139325A (en) * | 1991-01-25 | 1992-08-18 | Oksman Henry C | Wide depth of focus power add to intraocular and contact lenses |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5348578A (en) * | 1991-10-23 | 1994-09-20 | Ppg Industries (France) S.A. | Products obtained from the reaction of amine-diol and a polyfunctional substance and application of such products to electroapplicable cationic paint compositions |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
ATE280180T1 (de) * | 1992-08-31 | 2004-11-15 | Ludwig Inst Cancer Res | Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5414610A (en) * | 1993-06-21 | 1995-05-09 | Ast Research, Inc. | Universal power converter with single, shared power transformation circuit |
US5696764A (en) * | 1993-07-21 | 1997-12-09 | Fujitsu Limited | ATM exchange for monitoring congestion and allocating and transmitting bandwidth-guaranteed and non-bandwidth-guaranteed connection calls |
US5851523A (en) | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
US5585461A (en) * | 1994-03-24 | 1996-12-17 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
WO1996015346A1 (fr) * | 1994-11-11 | 1996-05-23 | Kabushiki Kaisha Tokai-Rika-Denki-Seisakusho | Dispositif d'acceptation de demarrage d'un vehicule et procede d'enregistrement d'un code d'identification |
DE4441903C1 (de) * | 1994-11-24 | 1996-03-21 | Siemens Ag | Drucksensor |
US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
AU7440196A (en) * | 1995-10-12 | 1997-04-30 | Chiron Corporation | Baboon mage-3 homologs, dna encoding the homologs, and a process for their use |
EP2724617A1 (de) | 2012-10-25 | 2014-04-30 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Verbindungen zum Abschwächen von Phosphatsterbesymptomen bei Pflanzen |
US9603182B2 (en) | 2013-03-14 | 2017-03-21 | Qualcomm Incorporated | Establishing reliable always-on packet data network connections |
-
1997
- 1997-09-12 US US08/928,615 patent/US5965535A/en not_active Expired - Lifetime
-
1998
- 1998-09-04 DE DE69840868T patent/DE69840868D1/de not_active Expired - Lifetime
- 1998-09-04 CA CA002303063A patent/CA2303063C/en not_active Expired - Fee Related
- 1998-09-04 WO PCT/US1998/018601 patent/WO1999014326A1/en active IP Right Grant
- 1998-09-04 EP EP98945923A patent/EP1012283B1/de not_active Expired - Lifetime
- 1998-09-04 AU AU93061/98A patent/AU757368B2/en not_active Ceased
- 1998-09-04 JP JP2000511865A patent/JP4106179B2/ja not_active Expired - Fee Related
- 1998-09-04 ZA ZA988124A patent/ZA988124B/xx unknown
- 1998-09-04 AT AT98945923T patent/ATE432983T1/de active
-
1999
- 1999-07-07 US US09/348,933 patent/US6369211B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2001516579A (ja) | 2001-10-02 |
WO1999014326A1 (en) | 1999-03-25 |
US5965535A (en) | 1999-10-12 |
CA2303063A1 (en) | 1999-03-25 |
EP1012283A1 (de) | 2000-06-28 |
ZA988124B (en) | 1999-03-05 |
AU757368B2 (en) | 2003-02-20 |
EP1012283B1 (de) | 2009-06-03 |
US6369211B1 (en) | 2002-04-09 |
CA2303063C (en) | 2009-11-24 |
DE69840868D1 (de) | 2009-07-16 |
AU9306198A (en) | 1999-04-05 |
JP4106179B2 (ja) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE432983T1 (de) | Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden | |
ATE427354T1 (de) | Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden | |
WO2002095051A3 (en) | Mage-a3 peptides presented by hla class ii molecules | |
EP0796913A3 (de) | GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine | |
MX344216B (es) | Productos geneticos expresados de forma diferencial en tumores y su uso. | |
DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
DE69637148D1 (de) | Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen | |
DE69333815D1 (de) | Gentranskription und ionisierende strahlung: methoden und zusammensetzungen | |
WO1999053061A3 (en) | Tumor associated nucleic acids and uses therefor | |
IL98682A (en) | Random bio-oligomer library a method of synthesis therefor and a method of use thereof | |
ATE209680T1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
ATE394484T1 (de) | Smad 6 und dessen anwendungen | |
NZ296748A (en) | Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods | |
NO984415L (no) | Peptider med antiproliferative egenskaper | |
ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
EP0815240A4 (de) | Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung | |
ATE496129T1 (de) | Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide | |
WO2004078918A3 (en) | Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides | |
ATE354657T1 (de) | Basb019 proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen | |
ATE475710T1 (de) | Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs | |
ATE341628T1 (de) | Proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1012283 Country of ref document: EP |